摘要
目的分析尤瑞克林治疗急性脑梗死后吞咽功能障碍的临床效果。方法择取医院就医的98例急性脑梗死后吞咽功能障碍患者,选取时间为2016年3月18日—2017年10月28日,通过随机颜色球抽取的方法将其分为两组。分别给予常规治疗、尤瑞克林治疗,对比两组神经功能缺损评分、日常生活能力评分、不良反应发生情况。结果观察组神经功能缺损评分为(8.54±0.54)分、日常生活能力评分为(14.69±0.66)分,与对照组相比,差异有统计学意义(P<0.05),但在不良反应发生情况的对比中,差异无统计学意义(P>0.05)。结论尤瑞克林治疗急性脑梗死后吞咽功能障碍效果显著,可缓解患者临床症状,安全有效。
Objective To analyze the clinical effect of urinary kallidinogenase on swallowing dysfunction after acute cerebral infarction. Methods Ninety-eight patients with swallowing dysfunction after acute cerebral infarction were enrolled in this study. The selected time ranged from March 18, 2016 to October 28, 2017, they were divided into two groups by random color ball extraction and were treated with routine treatment and urinary kallidinogenase, respectively. The scores of nerve function defect, daily life ability score and adverse reaction were compared between the two groups. Results The score of neurological deficit in the observation group was （8.54 ± 0.54） points and the daily living ability score was （14.69±0.66） points, the difference was significant compared with the control group, P 〈 0.05, but the incidence of adverse reactions in the difference was not signifcant, P 〉 0.05. Conclusion The effect of eriocaine on swallowing dysfunction after acute cerebral infarction is significant, which can relieve the clinical symptoms, is safe and effective and can be promoted.
作者
万琦
吴佳羽
WAN Qi;WU Jiayu(Neurology Department, The 101st Hospital of Chinese People＇s Liberation Army, Wuxi Jiangsu 214044, China)
出处
《中国继续医学教育》
2017年第35期91-93,共3页
China Continuing Medical Education
关键词
尤瑞克林
急性脑梗死
吞咽功能障碍
临床效果
评价
urinary kallidinogenase
acute cerebral infarction
swallowing dysfunction
clinical effect
evaluation
